EVALUATION OF POSSIBLE MOLECULAR MECHANISMS INVOLVED IN THE REGULATION OF HENT1 EXPRESSION IN ICC...

Employer
ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA - - DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE
Location
Italy
Posted
September 26 2017
Position Type
Full Time
Organization Type
Academia

Cholangiocarcinoma (CCA) encompasses a heterogeneous group of malignancies arising from cholangiocytes. Currently, chemotherapy with gemcitabine represents the standard of advanced CC treatment, but limited data are available on specific biomarkers predicting response to such treatment. We have recently demonstrated how the localization of the hENT-1 nucleoside transporter, required for gemcitabine uptake, on tumor cell membrane is a predictive factor of response to this treatment in intrahepatic CCA patients. Since one-third of gemicitabine-treated patients are negative for the expression of hENT-1 and to date, the molecular mechanism involved in the regulation of its expression remains unsettled, the purpose of the project will be to evaluate the possible molecular mechanisms underlying the lack of expression of this transporter in ICCA patients, focusing on the expression of specific miRNAs.



This job comes from a partnership with Science Magazine and Euraxess